BTK Inhibitors: An Emerging Target in Multiple Sclerosis

1.How many years have you been in practice?(Required.)

≥21

11-20

1-10

<1

2.How many patients with MS do you manage each week?(Required.)

1 to 10

11 to 25

26 or more

I am not directly involved in patient care

3.Please select the option that best describes your practice setting:(Required.)

4.After participating in this activity, how confident are you in the management of patients with MS in your practice?(Required.)

5.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

If not committed or do not plan to make changes, please indicate reason

6.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

7.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)

Greater understanding of the rationale for BTK inhibition in the management of MS

Increased awareness of the potential for improvements in MS treatment outcomes with BTK inhibition

Improved knowledge of the mechanism of action of emerging BTK inhibitor therapies for MS treatment

Greater knowledge of how these mechanisms may directly translate into therapeutic benefits for patients with MS

Increased knowledge regarding clinical trial safety and efficacy data on emerging BTK inhibitors in MS

Greater knowledge of how to monitor and manage the potential side effects of BTK inhibitor therapy

8.What barriers do you see to making changes in your practice? Please select all that apply.(Required.)

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

12.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

13.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for MS:

14.If you indicated that you perceived commercial bias or influence, please describe:

BTK Inhibitors: An Emerging Target in Multiple Sclerosis - Evaluation (ID: i849-2)